

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Adam, G	Examiner:	Martin, Paul C.
Serial No.:	10/607,806	Group Art Unit:	1655
Filed:	June 27, 2003	Docket:	SEQ-4032-UT
Conf. No.:	6270		
Title:	THERAPEUTIC METHODS FOR REDUCING FAT DEPOSITION AND TREATING ASSOCIATED CONDITIONS		

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam,

In compliance with the duty under 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the Examiner's attention for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form SB08A be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicants request that a copy of the SB08A form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication. Applicants also bring to the Examiner's attention the existence of the following co-pending related applications: (1) application no. 10/455,552 filed June 4, 2003 and published January 29, 2004 as US2004-0018533 A1 (Attorney Docket No. SEQ-4030-UT, Examiner Terra C, Gibbs), and (2) application no. 10/608,296 filed June 27, 2003 and published October 27, 2005 as US2005-

INFORMATION DISCLOSURE STATEMENT

Serial No.: 10/607,806

Filing Date: June 27, 2003

Title: THERAPEUTIC METHODS FOR REDUCING FAT DEPOSITION AND TREATING ASSOCIATED CONDITIONS

Page 2

Dkt: SEQ-4032-UT

0239077 A1 (Attorney Docket No. SEQ-4031-UT, Examiner Jehanne S. Sitton).

The documents referenced in the attached Form SB08 were cited in a supplemental search report from the European Patent Office dated September 15, 2006. Therefore, each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The listed documents are being submitted in compliance with 37 CFR § 1.97(d), after the mailing date of a final Office action. Accordingly, Applicants respectfully submit payment of \$180.00.

If any additional fees are due, please contact the undersigned attorney at (858) 623-9470. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

Date: December 13, 2006

By: /Bruce Grant/

Bruce Grant
Reg. No. 47608
Attorney for Applicants
BioTechnology Law Group
Customer No. 47328
Telephone: (858) 623-9470

Substitute for form 1449A/PTD

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Consistently Known

Application Number	10/607,806
Filing Date	June 27, 2003
First Named Inventor	Gail Adam
Group Art Unit	1655
Examiner Name	Martin, Paul C.

Sheet 1 of 1

Attorney Docket No: SEQ-4032-UT

US PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1.	56211233	04/15/1997	Johnson et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	A2.	EP 0356454	10/20/1988	Bundy and Youngdale		

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
	A3.	Huggins et al., Gastroenterology, 120(5, sup1):A42 #214 Meeting Abstract	
	A4.	Huggins et al., Gastroenterology, 120(5, sup1):A58 #491 Meeting Abstract	
	A5.	Huggins et al., Am. J. Physiol., 283(5):E994-E1001	
	A6.	Homan et al., J. Lipid Research, 39(6):1197-1209	
	A7.	European Patent Office Supplementary Search Report	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTD 1449)

* EXAMINER: Initial of reference considered, whether or not citation is a performance with MPEP 806. Disclose through citation if not a performance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designator number (optional). Applicant is to place a check mark here if English language Translation is attached.